Redpoint

RedPoint Oncology is a private precision oncology biotechnology company developing next-generation targeted therapies for therapy-resistant and metastatic solid tumors. The company is centered on advanced conjugate approaches, including antibody-drug conjugates and antibody-siRNA conjugates, designed to exploit vulnerabilities in resistant cancer cells. Publicly available descriptions indicate an early pipeline with multiple preclinical assets and a lead focus in metastatic triple-negative breast cancer. RedPoint Oncology appears to be very early stage, with a small team based in Holden, Massachusetts and participation in accelerator and startup support programs such as MassBioDrive, MassChallenge, and SBIR-related funding. The company is best characterized as an emerging platform oncology startup rather than a clinical-stage drug developer.